Moderna (MRNA) said Wednesday that it has voluntarily withdrawn its Biologics License Application for mRNA-1083, its flu and COVID combination vaccine candidate for adults aged 50 and older.

The biotech firm said it will resubmit the BLA after vaccine efficacy data from a late-stage trial of its investigational seasonal influenza vaccine mRNA-1010 are available.

Moderna said it expects interim data from the mRNA-1010 trial to be available this summer.

The decision to withdraw the license was made in consultation with the US Food and Drug Administration, the company said.

Shares of Moderna were down 1.4% in recent Wednesday premarket activity.